Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Abivax SA Sponsored ADR ( (ABVX) ) has provided an announcement.
On July 23, 2025, Abivax SA entered into an underwriting agreement with Leerink Partners LLC, Piper Sandler & Co., and Guggenheim Securities, LLC for a public offering of 10,156,000 American Depositary Shares (ADSs) at $64.00 per share. The offering is expected to generate approximately $608.6 million in net proceeds, with the closing anticipated on July 28, 2025. This move is part of Abivax’s strategy to strengthen its financial position and support its ongoing research and development efforts, potentially enhancing its market presence and stakeholder value.
The most recent analyst rating on (ABVX) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Abivax SA Sponsored ADR stock, see the ABVX Stock Forecast page.
Spark’s Take on ABVX Stock
According to Spark, TipRanks’ AI Analyst, ABVX is a Neutral.
Abivax SA’s overall stock score is primarily impacted by its poor financial performance, characterized by operational losses and high leverage. While technical analysis shows bullish momentum, the valuation remains unattractive due to negative earnings. Without additional positive catalysts or improvements in profitability, the stock faces significant risks.
To see Spark’s full report on ABVX stock, click here.
More about Abivax SA Sponsored ADR
Abivax SA is a French biopharmaceutical company focused on developing and commercializing therapies for inflammatory diseases and cancer. The company is known for its innovative approach in the biotechnology sector, particularly in the development of small molecules and biologics.
Average Trading Volume: 873,824
Technical Sentiment Signal: Hold
Current Market Cap: $4.06B
See more data about ABVX stock on TipRanks’ Stock Analysis page.